Resilience and Equity in Aging, Cancer, and Health (REACH): Promoting Physical Resilience and Cancer Care Equity for Adults Age 70 and Older Diagnosed With Gastrointestinal Malignancy
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 70
Healthy Volunteers: f
View:
• Patients who are age 70+ at time of initial consult at DF/BWCC
• Diagnosed with a gastrointestinal cancer, including: cancers of the esophagus, stomach, pancreas, liver, bile duct, ampulla, colon, rectum, or anus, as well as neuroendocrine tumors.
• Continuing care at DF/BWCC beyond initial consult visit
• English and Spanish-speaking
Locations
United States
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Boston
Contact Information
Primary
Nadine J McCleary, MD, MPH
NJ_McCleary@dfci.harvard.edu
877-442-3324
Time Frame
Start Date: 2022-01-18
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 257
Treatments
Experimental: Intervention Phase - Geriatric Co-Management
Eligible older adults age 70 and older who score Pre-Frail or Frail will be randomized 2:1 to be offered to meet with a study geriatrician for geriatric co-management in addition to their standard oncology care. Study geriatrician will assist with management of symptoms, additional comorbidities, polypharmacy, and social/emotional concerns in addition to physical care. Geriatrician can make referrals and recommendations for additional supportive services that may be beneficial for more vulnerable older adult patients.
No_intervention: Intervention Phase - Standard Oncology Care
This arm is for those older adult patients (age 70+) who score as Pre-Frail or Frail in the fitness assessment questionnaire and are NOT randomized to meet with the study geriatrician. These patients will be followed for the duration of the study as they proceed with their usual oncology care. Study team will evaluate a number of different measures and outcomes, the primary one being unplanned emergency and hospital visits during the course of the study.
Related Therapeutic Areas
Sponsors
Leads: Dana-Farber Cancer Institute